Advertisement

Topics

Fragile X Syndrome Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

12:30 EDT 3 Aug 2017 | BioPortfolio Reports

DelveInsight's, Fragile X Syndrome Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Fragile X Syndrome. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Fragile X Syndrome. This report provides information on the therapeutic development for Fragile X Syndrome, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Aelis Farma SAS AMO Pharma Ltd Anavex Life Sciences Corp Confluence Pharmaceuticals LLC DRI Biosciences Corp Eli Lilly and Company Fulcrum Therapeutics Inc GlaxoSmithKline Plc GW Pharmaceuticals Plc Marinus Pharmaceuticals Inc Neuren Pharmaceuticals Ltd Neuron Biopharma SA Ovid Therapeutics Inc Sage Therapeutics Inc and Zynerba Pharmaceuticals Inc.
Fragile X Syndrome Pipeline Drugs
Fragile X Syndrome Pipeline Assessment
Fragile X Syndrome Pipeline Analysis
Fragile X Syndrome Drugs under Development
Fragile X Syndrome Discovery drugs
Fragile X Syndrome Preclinical drugs
Fragile X Syndrome Phase I drugs
Fragile X Syndrome Phase II drugs
Fragile X Syndrome Phase III Pipeline Drugs Assessment
Fragile X Syndrome Preregistration drugs
Fragile X Syndrome Molecules in pipeline

Original Article: Fragile X Syndrome Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Fragile X Syndrome Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...